ABSTRACT
Calendario de Inmunizaciones 2024 de población infantil, escolar y adulta.
Subject(s)
Respiratory Syncytial Viruses , BCG Vaccine , Influenza Vaccines , Smallpox Vaccine , Vaccines , Viral Hepatitis Vaccines , Diphtheria-Tetanus-Pertussis Vaccine , Chile , Immunization , Hepatitis B Vaccines , Vaccines, Combined , Immunization Programs , Chickenpox Vaccine , Meningococcal Vaccines , Pneumococcal Vaccines , Measles-Mumps-Rubella Vaccine , Yellow Fever Vaccine , Papillomavirus Vaccines , Heptavalent Pneumococcal Conjugate Vaccine , COVID-19 VaccinesABSTRACT
A fines de 2023 la autoridad sanitaria de Argentina realizó modificaciones en el Calendario Nacional obligatorio, que serán implementadas en forma progresiva durante 2024. Este artículo está enfocado en la reducción del esquema contra el virus del papiloma humano. (AU)
At the end of 2023, the Argentine health authority modified the mandatory National Calendar, which will be implemented progressively during 2024. This article focuses on the reduction in the human papillomavirus scheme. (AU)
Subject(s)
Humans , Female , Papillomavirus Infections/prevention & control , Papillomavirus Vaccines/administration & dosage , Vaccine Efficacy , Argentina/epidemiology , Uterine Cervical Neoplasms/prevention & control , Public Health/methods , Immunization Schedule , Treatment Outcome , Papillomavirus Infections/virology , Papillomaviridae/immunologySubject(s)
Humans , Male , Female , Child , Adolescent , Immunization Schedule , Papillomavirus Vaccines , Demography , Sanitary SupervisionABSTRACT
INTRODUCCIÓN: El virus del papiloma humano (VPH), con más de 100 tipos, es de transmisión sexual. Varios países de América Latina han introducido las vacunas contra el VPH. Aunque América Latina es la región que más rápido avanzó en la vacunación contra el VPH, sus sistemas de seguimiento y vigilancia son aún deficientes. OBJETIVO: Comparar las diferentes estrategias de vacunación contra el VPH en Ecuador y América Latina. MÉTODO: Revisión bibliográfica, en la que se obtuvo información de documentos gubernamentales y artículos indexados en los últimos 5 años sobre las estrategias de vacunación contra el VPH en Ecuador y América Latina. RESULTADOS: La mayoría de los países de América Latina han logrado introducir la vacuna contra el VPH, excepto Venezuela, Martinica, Haití, Nicaragua y Cuba. CONCLUSIONES: Los protocolos de vacunación de Ecuador y América Latina necesitan mejorar sus sistemas de seguimiento y aumentar la expansión de datos de cobertura disponibles de manera consistente. Actualmente siguen existiendo desafíos para introducir las vacunas, lograr una alta cobertura y fortalecer el seguimiento, la evaluación y la notificación.
INTRODUCTION: The human papilloma virus (HPV), with more than 100 types, is a sexual transmission infection. Many Latin American countries have introduced the vaccines against the HPV. Although Latin América is the region which advanced faster against the HPV, its surveillance and follow-up systems are yet deficient. OBJECTIVE: To compare the different strategies to assume the vaccination against the HPV in Ecuador and Latin America. METHOD: Bibliographic review, in which information was obtained from government documents and articles indexed in the last five years on vaccination strategies against HPV in Ecuador and Latin America. RESULTS: Most Latin American countries have managed to introduce the vaccine against the HPV, except Venezuela, Martinica, Haiti, Nicaragua and Cuba. CONCLUSIONS: The vaccination protocols of Ecuador and Latin América need to improve their systems of follow-up and monitoring, and increase the expansion of available data in a consistent manner. Now, there are still existing challenges to introduce the vaccines, manage a high reach and fortify the follow-up, the evaluation, and the notification.
Subject(s)
Humans , Female , Immunization Programs , Papillomavirus Infections/prevention & control , Papillomavirus Vaccines , Immunization Schedule , Ecuador , Latin AmericaABSTRACT
Introducción: La cobertura de vacunación contra el virus del papiloma humano no se ha realizado en la totalidad de la población, existen factores que interfieren en que los padres de las adolescentes acepten su aplicación. Objetivo: Relacionar el conocimiento sobre el virus del papiloma humano, el conocimiento sobre la vacuna contra el virus, las creencias sobre la vacuna con la aceptabilidad de la vacuna por los padres de las adolescentes de 9-12 años escolarizadas en Chihuahua, México.Materiales y Métodos: Estudio de tipo descriptivo, correlacional y transversal, la muestra fue de tipo censal, se conformó por 145 padres de niñas entre 9 a 12 años inscritas en tres primarias públicas ubicadas en una zona urbana de Chihuahua, México. Resultados: El conocimiento sobre el virus del papiloma humano se relacionó con la aceptabilidad de la vacuna (p < 0,009), de igual manera con el conocimiento acerca de la vacuna del virus del papiloma humano (p < 0,030) mientras que las creencias sobre el VPH y la vacuna no se relacionaron (p < 0, 747). Discusión: Los resultados coinciden con literatura previa en que el conocimiento sobre el virus y su vacuna es bajo, sin embargo, en este estudio las puntuaciones fueron más bajas. Mientras que la aceptabilidad de la vacuna contra el VPH tiende a ser alta al igual que estudios previos. Conclusiones: El conocimiento sobre el virus del papiloma humano y la vacuna se relacionaron con la aceptabilidad de los padres para aplicar la vacuna a sus hijas.
Introduction: Human papillomavirus vaccination coverage has not been achieved in the general population. There are factors that interfere with the acceptance of the vaccine by the parents of adolescent girls. Objective: To correlate knowledge of human papillomavirus, knowledge of the vaccine against the virus, and beliefs about the vaccine with vaccine acceptance among parents of adolescent girls aged 9-12 years in Chihuahua, Mexico. Materials and Methods: A descriptive, correlational, and cross-sectional study was conducted with a census sample of 145 parents of girls between the ages of 9 and 12 enrolled in three public elementary schools in an urban area of Chihuahua, Mexico. Results: Knowledge of human papillomavirus was related to vaccine acceptance (p < 0.009), as was knowledge of the human papillomavirus vaccine (p < 0.030). In contrast, beliefs about HPV and the vaccine were not related (p < 0.747). Discussion: The results are consistent with previous literature in that knowledge of the virus and its vaccine is low, but the scores were lower in this study. In contrast, HPV vaccine acceptance tends to be high, as in previous studies. Conclusions: Knowledge about human papillomavirus and the vaccine was associated with parental acceptance of giving it to their daughters.
Introdução: A cobertura vacinal contra o papilomavírus humano não tem sido realizada em toda a população, existem fatores que interferem na aceitação da sua aplicação pelos pais de meninas adolescentes. Objetivo: Relacionar o conhecimento sobre o papilomavírus humano, o conhecimento sobre a vacina contra o vírus, as crenças sobre a vacina com a aceitabilidade da vacina pelos pais de meninas adolescentes de 9 a 12 anos que frequentam a escola em Chihuahua, México. Materiais e Métodos: Estudo descritivo, correlacional e transversal, a amostra foi do tipo censitária, composta por 145 pais de meninas entre 9 e 12 anos matriculadas em três escolas primárias públicas localizadas em uma área urbana de Chihuahua, México. Resultados: O conhecimento sobre o papilomavírus humano esteve relacionado com a aceitabilidade da vacina (p < 0,009), da mesma forma com o conhecimento sobre a vacina contra o papilomavírus humano (p < 0,030), enquanto as crenças sobre o HPV e a vacina não foram relacionadas (p < 0,747). Discussão: Os resultados coincidem com a literatura anterior na medida em que o conhecimento sobre o vírus e sua vacina é baixo, porém, neste estudo as pontuações foram inferiores. Embora a aceitabilidade da vacina contra o HPV tenda a ser elevada como em estudos anteriores. Conclusões: O conhecimento sobre o papilomavírus humano e a vacina esteve relacionado à aceitabilidade dos pais em aplicar a vacina em suas filhas.
Subject(s)
Parents , Patient Acceptance of Health Care , Knowledge , Papillomavirus VaccinesABSTRACT
OBJETIVO: Analisar a situação vacinal contra o papilomavírus humano entre estudantes da Faculdade de Medicina da Universidade Federal de Juiz de Fora. MÉTODOS: Trata-se de um estudo observacional transversal, que visa identificar e analisar as características e variáveis que se relacionam com a situação vacinal contra o papilomavírus humano de discentes da Faculdade de Medicina da Universidade Federal de Juiz de Fora. Os dados foram coletados por meio de questionários online padronizados. RESULTADOS: Entre os participantes, 176 (49,2%) alegaram serem vacinados contra o vírus e receberam, no mínimo, uma dose da vacina. Dentre os pesquisados, 74 (20,7%) estudantes declararam terem tomado 3 doses, enquanto 89 (24,9%) tomaram 2 e 13 (3,6%) tomaram apenas 1 dose. Com relação aos vacinados na faixa etária abrangida pela rede pública, 62 (17,3%) são do sexo feminino (9-14 anos) e 12 (3,4%) são do sexo masculino (11-14 anos). Sobre os discentes que já apresentaram alguma lesão pelo vírus, 66,66% não foram vacinados. CONCLUSÃO:Com o presente estudo, foi possível evidenciar que, assim como ocorre com a população brasileira em geral, a situação vacinal contra o papilomavírus humano entre estudantes da Faculdade de Medicina da Universidade Federal de Juiz de Fora está aquém do esperado. O principal motivo relatado para a não vacinação foi não fazer parte da faixa etária incluída na vacinação da rede pública. Constatou-se também que a prevalência de lesão por Papilomavírus Humano em vacinados foi menor que nos não vacinados, enfatizando a necessidade da vacina para prevenção de lesões causadas pelo vírus (AU).
OBJECTIVE: Analyze the vaccination status against the human papillomavirus among students at the School of Medicine of the Federal University of Juiz de Fora. METHODS: It is an observational cross-sectional study that aims to identify and analyze the characteristics and variables that relate to the vaccination status against the human papillomavirus of students at the School of Medicine of the Federal University of Juiz de Fora. The data were collected using standardized online questionnaires. RESULTS: Among the participants, 176 (49.2%) claimed to have been vaccinated against the virus and had received at least one dose of the vaccine. Among those surveyed, 74 (20.7%) students reported having taken 3 doses, while 89 (24.9%) took 2 and 13 (3.6%) took only 1 dose. Regarding the vaccinated in the age group covered by the public network, 62 (17.3%) are female (9-14 years old) and 12 (3.4%) are male (11-14 years old). A total of 66.66% of the students who have already had some injury by the virus, were not vaccinated. CONCLUSION: This study showed that, as with the Brazilian population in general, the vaccination status against human papillomavirus among students at the School of Medicine of the Federal University of Juiz de Fora is below expectations. The main reason reported for non-vaccination was not being part of the age group included in the vaccination of the public network. It was also found that the prevalence of lesions by Human Papillomavirus in vaccinated was lower than in non-vaccinated, emphasizing the need for the vaccine to prevent lesions caused by the virus (AU).
Subject(s)
Humans , Students, Medical , Papillomavirus Infections , Vaccination Coverage , Papillomavirus VaccinesABSTRACT
Introduction: Human Papillomavirus (HPV) infections are of significant concern in men, given its potential impact on their health and the risk of transmission to partners. Understanding and addressing this infection in men is crucial to evaluate the effectiveness of vaccination in reducing HPV-related diseases. Objective: To assess the impact of HPV vaccination, potential genotype shifts, and adverse effects, through a prospective study conducted with male university students. Methods:The study involved 286 volunteers who were examined at Sexually Transmitted Disease Clinics at the Universidade Federal Fluminense in Niterói, Rio de Janeiro, Brazil. The HPV prevalence was evaluated using generic PCR, genotyped by DNA microarray and monitored adverse effects. Results: The findings of this study revealed the absence of moderate or severe adverse effects. Genetic shifts were observed, including the disappearance of oncogenic HPV types 16 and 18. Surprisingly, even after completing the full vaccine regimen, students still harbored HPV11 in the oral tract. Furthermore, persistent HPV 6 and 11 infections were identified in three students, who had pre-existing infections prior to vaccination, at the follow-up visit. Multivariate analysis uncovered independent associations, notably an increased risk of HPV infection in the oral tract among men who have sex with men. HPV prevalence rates remained low both before and after the vaccination scheme (T0: 14.7%, T1: 8.7%). Even after the full vaccination scheme, the prevalence remained similar at T2 (14.6%), with no statistically significant differences recorded. HPV11 emerged as the most prevalent type throughout the study, followed by HPV6. Vaccine genotypes were detected in a significant proportion of samples at T0 (85.4%), T1 (89.5%), and T2 (100%). Conclusion: Overall, this study suggests that vaccination may represent a promising approach to reducing HPV-related health risks. These findings shed light on the potential benefits and challenges of HPV vaccination, emphasizing the need for continued monitoring and vaccination efforts
Introdução: As infecções por papilomavírus humano (HPV) são de grande preocupação em homens, dada sua possível influência na saúde deles e no risco de transmissão para parceiros. Compreender e abordar essa infecção em homens é fundamental para avaliar a eficácia da vacinação na redução de doenças relacionadas ao HPV. Objetivo: Avaliar o impacto da vacinação contra o HPV, possíveis alterações genotípicas e efeitos adversos, por meio de um estudo prospectivo realizado em estudantes universitários do sexo masculino. Métodos: O estudo envolveu 286 voluntários examinados em Clínicas de Doenças Sexualmente Transmissíveis na Universidade Federal Fluminense, em Niterói, Rio de Janeiro, Brasil. A prevalência do HPV foi avaliada por polymerase chain reaction (PCR) genérico e genotipada por microarranjo de DNA, e foram monitorados os efeitos adversos. Resultados: Os resultados deste estudo revelaram a ausência de efeitos adversos moderados ou graves. Observaram-se mudanças genéticas, incluindo o desaparecimento dos tipos oncogênicos do HPV 16 e 18. Surpreendentemente, mesmo após a conclusão do esquema completo de vacinação, os estudantes ainda abrigavam o HPV 11 na cavidade oral. Além disso, foram identificadas infecções persistentes pelo HPV 6 e 11 em três estudantes que já tinham infecções preexistentes antes da vacinação e na visita de acompanhamento. A análise multivariada revelou associações independentes, especialmente um aumento no risco de infecção pelo HPV na cavidade oral em homens que têm relações sexuais com homens. As taxas de prevalência do HPV permaneceram baixas tanto antes quanto depois do esquema de vacinação (T0: 14,7%, T1: 8,7%). Mesmo após a conclusão do esquema de vacinação, a prevalência permaneceu semelhante em T2 (14,6%), sem diferenças estatisticamente significativas registradas. O HPV 11 emergiu como o tipo mais prevalente ao longo do estudo, seguido pelo HPV 6. Genótipos da vacina foram detectados em uma proporção significativa de amostras em T0 (85,4%), T1 (89,5%) e T2 (100%). Conclusão: No geral, este estudo sugere que a vacinação pode representar uma abordagem promissora para a redução dos riscos à saúde relacionados ao HPV. Esses achados lançam luz sobre os benefícios e desafios potenciais da vacinação contra o HPV, enfatizando a necessidade de monitoramento contínuo e esforços de vacinação
Subject(s)
Humans , Male , Adolescent , Young Adult , Papillomavirus Infections/prevention & control , Papillomavirus Vaccines/administration & dosage , Papillomaviridae/genetics , Brazil/epidemiology , Prospective Studies , Papillomavirus Infections/epidemiology , GenotypeABSTRACT
INTRODUCTION@#Cervical cancer has a high disease burden in Singapore, and it is strongly associated with human papillomavirus (HPV) infections. Despite constant efforts to encourage vaccination, local HPV vaccine uptake remains low. Universal mass vaccination is a proven cost-effective method to reduce the cervical cancer disease burden. This paper reviews the newly implemented school-based HPV vaccination programme in Singapore and the factors that led to its success.@*METHODS@#Fully subsidised HPV vaccinations were offered to all Secondary 1 female students on an opt-in basis, starting as a rollout dose in 2019. One-time catchup vaccination was also offered to female students in Secondary 2-5. Eligible recipients were identified using enrolment data provided by Ministry of Education schools. A total of 19,144 students across 139 schools were offered the rollout dose, and 20,854 students across 140 schools were offered the catchup doses.@*RESULTS@#High vaccine uptake rates of 80.6%-87.3% were noted with the introduction of the school-based programme, translating to high vaccine coverage of 90.3%-93.4%. Only a small proportion of students (1.5%-1.9% per cohort) opted out. The rate of reported side effects, which were commonly known effects, was low at one in 1000. Among the students who reported side effects, those who received the second vaccine dose did so uneventfully.@*CONCLUSION@#High HPV vaccine coverage was achieved after implementation of the school-based immunisation programme. Timely assessment of knowledge lapses and targeted intervention, strong partnerships with stakeholders, constant on-site adaptation and positive social influence contributed to its success. This model can be applied to future school health programmes.
Subject(s)
Humans , Female , Papillomavirus Vaccines/therapeutic use , Papillomaviridae , Papillomavirus Infections/prevention & control , Singapore , Uterine Cervical Neoplasms/epidemiology , Vaccination , Immunization ProgramsABSTRACT
The efficacy of HPV vaccine in preventing cervical cancer has been demonstrated in numerous clinical trials and clinical uses. The follow-up after clinical trials usually last for 5-6 years to evaluate the long-term efficacy, and a series of long-term follow-up studies have been conducted in some regions. The literature retrieval of HPV vaccine long term efficiency research both at home and abroad indicated that the protective efficacy of the vaccine against vaccine-type-related cervical intraepithelial neoplasia grade 2 and above is higher than 90%.
Subject(s)
Humans , Papillomaviridae , Biomedical Research , Papillomavirus VaccinesABSTRACT
Persistent infection of high-risk human papillomavirus (HPV) is the leading cause of cervical cancer. In order to achieve the goal of cervical cancer elimination, the World Health Organization (WHO) proposed the "90-70-90" goal, one of which is "90% of girls fully vaccinated with HPV vaccine by age 15 years". Based on the epidemiological characteristics of HPV infection and the characteristics of HPV vaccine, it is important to give priority to female adolescents to be vaccinated with HPV vaccine. CAV Affiliated Association for Standardized Management and Practice of Immunization Program organized an expert group to develop an expert consensus on the immunization strategy and practice of human papillomavirus vaccine for female adolescents in the Yangtze River Delta region. This consensus introduces HPV infection and related disease burden, safety, efficacy and effectiveness of HPV vaccination for female adolescents, factors affecting the health benefits of HPV vaccination for female adolescents, current HPV vaccination strategies for female adolescents, the expert advice, common problems and precautions in the Yangtze River Delta region. This consensus is developed to guide HPV vaccination for female adolescents in the Yangtze River Delta region and provide reference for other regions.
Subject(s)
Female , Adolescent , Humans , Papillomavirus Vaccines , Papillomavirus Infections/prevention & control , Papillomaviridae , Uterine Cervical Neoplasms/prevention & control , Consensus , Vaccination , Immunization ProgramsABSTRACT
Cervical cancer mainly caused by human papillomavirus (HPV) infection has become a public health issue, which seriously threatens women 's health. To prevent HPV infection, the currently used prophylactic vaccines mainly induce a humoral immune response in the host, thereby generating neutralizing antibodies. In contrast, the design goal of therapeutic HPV vaccines is to induce a cell-mediated immune response in the host, primarily driven by Th1 cells, aiming to clear existing viral infections and slow down or inhibit tumor progression. Currently, several therapeutic HPV vaccines based on different mechanisms and techniques have entered clinical trials. This review will summarize the progress of these clinical trials, providing reference for the research and development of therapeutic HPV vaccines.
Subject(s)
Female , Humans , Papillomavirus Vaccines/therapeutic use , Papillomavirus Infections/prevention & control , Uterine Cervical Neoplasms , Immunity, Cellular , PapillomaviridaeABSTRACT
This study systematically retrieved information on the payment policy of vaccination fees for pneumococcal vaccines, human papillomavirus vaccines, haemophilus influenzae type b vaccines and rotavirus vaccines using a Python-based crawler. The proportion of the population covered by policies among the total applicable population was estimated based on the medical insurance coverage ratio and population data in 2020. This study showed that the payment policies included two categories, government-funded free vaccination policies and medical insurance payment policies. Among the four non-national immunization program vaccines, the free vaccination policies only involved pneumococcal vaccines and human papillomavirus vaccines. Among them, the 13-valent pneumococcal conjugate vaccine, the 23-valent pneumococcal polysaccharide vaccine, and the human papillomavirus vaccine were provided free of charge in 1, 10 and 15 provinces, respectively. For these policies, the corresponding covered population and the proportion among the total applicable population were children aged 6 months to 2 years old (2.5%), older people (1.2% to 21.5%) and middle school girls (1.1% to 12.2%). Medical insurance payment policies were implemented in 14 provinces, and nearly covered the four types of vaccines in the policy implementation areas, with the proportion of the covered population about 10.9% to 41.5% among the total applicable population.
Subject(s)
Child , Female , Humans , Infant , Aged , Pneumococcal Vaccines , Vaccination , Policy , Immunization Programs , Papillomavirus Vaccines , China , Vaccines, ConjugateABSTRACT
Objective: To systematically collect and evaluate the health economics research of Human papilloma virus(HPV) vaccination population expansion to men, and to provide evidence for optimizing HPV vaccine immunization strategies. Methods: Health economics research studies on male HPV vaccination published in databases including PubMed, Web of Science, CNKI, and Wanfang Database from January 2010 to September 2022 were collected according to the systematic evaluation research design. The quality of the studies was assessed using the health economics evaluation reporting standards (2022 edition) (CHEERS 2022), with full score of 28. The results of the studies were reviewed and analyzed systematically. Results: A total of 21 studies complies with the criteria were included, all of which was foreign research. The average CHEERS score of the literatures was 25.71 points, range from 23 to 28 points. 85.71% (12/14) studies of the gender-neutral population showed that including male in HPV vaccination were more consistent with the cost effectiveness than female vaccination alone under certain conditions (target at adolescents of 10 to 15 years old or adults under 26 years old). 80.00% (4/5) of the studies target at ordinary men only were proved that male vaccination with HPV vaccine was in line with the cost-effectiveness. 2 studies targeting men who have sex with men (MSM) were both concluded that it met the cost-effectiveness. In addition, the results of 2 gender-neutral population studies and 1 study on men alone showed that extending HPV vaccination to men did not conform to cost effectiveness. The main reasons for the non-cost-effectiveness included the high price of vaccines and the age of vaccination. Conclusion: The quality of the health economics evaluation studies on expanding HPV vaccination to the male population is high. Vaccination targeting adolescents and young men as well as special groups (such as MSM) are likely to be cost-effective, and vaccinations for other groups are still need further evaluated. It is recommended that relevant research should be conducted to provide evidence for expanding the scope of HPV vaccination to men in China.
Subject(s)
Adult , Adolescent , Humans , Male , Female , Child , Papillomaviridae , Homosexuality, Male , Papillomavirus Infections/prevention & control , Sexual and Gender Minorities , Cost-Benefit Analysis , Vaccination , Immunization , Papillomavirus VaccinesABSTRACT
Objective: To understand the setting of adult vaccination clinics and the situation of adult vaccination in Shandong province, and provide the date basis for the construction and development of adult vaccination clinics in Shandong province. Methods: Multi-stage stratified cluster random sampling was used to survey the settings, personnel allocation, operation status, and adult vaccination status of child-adult vaccination clinics and adult vaccination clinics. A random sampling survey was conducted for hydrophobia vaccination clinics in 12 counties (cities, districts) of Shandong province. The settings and vaccination status of different types of adult vaccination clinics were compared and analyzed using analysis of variance or χ2-test. Results: Among the investigated counties (cities, districts), the child-adult vaccination clinics, the adult vaccination clinics, and the hydrophobia vaccination clinics accounted for 59.51%, 7.97% and 32.52%, respectively. The construction model could be divided into three models: child-adult vaccination clinic model, child-adult and hydrophobia vaccination clinic model, child-adult, adult and hydrophobia vaccination clinic model. The child-adult vaccination clinics had been set up for a long time (≥3 years accounted for 94.33%) and were set up by public primary medical institutions (public institutions accounted for 93.81% and primary institutions accounted for 92.78%). Each vaccination clinic was equipped with full-time and part-time staff of (3.19±3.01) and (3.72±4.32). The adult vaccination clinics had been set up for a short time (≥3 years accounted for 94.33%) and were set up by public/private primary/secondary medical institutions in urban areas (urban areas accounted for 100%, primary institutions accounted for 69.23%, and private institutions accounted for 57.69%). Each vaccination clinic was equipped with full-time and part-time staff of (2.46±2.87) and (3.08±3.53). The coverage of influenza vaccine (InfV), human papillomavirus vaccine (HPV) and hepatitis B vaccine (Hep B) reached 100%, 98.45% and 97.42% in children-adult vaccination clinics, and 88.46%, 84.62% and 73.08% in adult vaccination clinics, respectively. The hydrophobia vaccination clinics only provided rabies vaccine for human use (RabV) and tetanus vaccine (TV) vaccination simultaneously. A total of 819.8 thousand doses of adult vaccines were administered in 2021. The adult inoculation doses of RabV, lnfV and HPV accounted for 42.60%, 27.47% and 17.54% of the total inoculation doses, respectively. The inoculation doses of InfV, HPV and RabV accounted for 49.33%, 21.97% and 13.80% of child-adult vaccination clinics, respectively. The inoculation doses of HPV, HepB and RabV accounted for 49.36%, 15.40% and 14.71% of adult vaccination clinics, respectively. The proportion of RabV reached 94.44% in the hydrophobia vaccination clinics alone. Conclusion: Adult vaccination is at the initial stage in Shandong province. The children's vaccination clinic is mainly responsible for adult vaccination. The variety of adult vaccines is relatively concentrated, and the adult vaccination rate is lower. The construction and publicity of adult vaccination should be further strengthened.
Subject(s)
Adult , Humans , Papillomavirus Infections , Rabies , Influenza Vaccines , Vaccination , Ambulatory Care Facilities , Papillomavirus VaccinesABSTRACT
Objective: To understand the current situation of vaccination services for adults in China, explore how to establish a stable and efficient vaccination service system for adults, and provide reference for formulating corresponding policies. Methods: The vaccination information systems of nine provinces in China were used to obtain information on urban and rural vaccination of influenza vaccine, 23-valent pneumococcal polysaccharide vaccine (PPV23), and human papillomavirus vaccine (HPV) from 2019 to 2021. The indicator, vaccination rate/full vaccination rate, was used for statistical description. Results: The vaccination rate/full vaccination rate of the three vaccines in eastern China was generally higher than that in central and western China. The vaccination rate/full vaccination rate in urban areas was generally higher than that in rural areas. From 2019 to 2021, the vaccination rates of influenza vaccine among people aged 60 years and above in urban and rural areas were 2.96%, 6.29%, 6.14% and 1.29%, 2.58%, 2.94%, respectively. The vaccination rates of the PPV23 among people aged 60 years and above in urban and rural areas increased year by year, with rates of 0.38%, 1.05%, 1.15% and 0.14%, 0.49%, 0.59%, respectively. From 2019 to 2021, the HPV coverage of female adults aged 27-45 years in urban and rural areas increased year by year, with rates of 0.46%, 0.93%, 1.88% and 0.17%, 0.40%, 1.08%, respectively. Conclusion: The vaccination rates of influenza vaccine,PPV23 vaccine and HPV vaccine for adults in China are relatively low, with higher rates in the eastern region than in the central and western regions, and higher rates in urban areas than in rural areas. It is recommended to formulate corresponding health and economic policies and explore a suitable vaccination service system for adults in China to improve vaccination rates.
Subject(s)
Adult , Female , Humans , Influenza Vaccines/therapeutic use , Papillomavirus Infections , Vaccination , China , Papillomavirus Vaccines/therapeutic useABSTRACT
Cervical cancer mainly caused by human papillomavirus (HPV) infection has become a public health issue, which seriously threatens women 's health. To prevent HPV infection, the currently used prophylactic vaccines mainly induce a humoral immune response in the host, thereby generating neutralizing antibodies. In contrast, the design goal of therapeutic HPV vaccines is to induce a cell-mediated immune response in the host, primarily driven by Th1 cells, aiming to clear existing viral infections and slow down or inhibit tumor progression. Currently, several therapeutic HPV vaccines based on different mechanisms and techniques have entered clinical trials. This review will summarize the progress of these clinical trials, providing reference for the research and development of therapeutic HPV vaccines.
Subject(s)
Female , Humans , Papillomavirus Vaccines/therapeutic use , Papillomavirus Infections/prevention & control , Uterine Cervical Neoplasms , Immunity, Cellular , PapillomaviridaeABSTRACT
This study systematically retrieved information on the payment policy of vaccination fees for pneumococcal vaccines, human papillomavirus vaccines, haemophilus influenzae type b vaccines and rotavirus vaccines using a Python-based crawler. The proportion of the population covered by policies among the total applicable population was estimated based on the medical insurance coverage ratio and population data in 2020. This study showed that the payment policies included two categories, government-funded free vaccination policies and medical insurance payment policies. Among the four non-national immunization program vaccines, the free vaccination policies only involved pneumococcal vaccines and human papillomavirus vaccines. Among them, the 13-valent pneumococcal conjugate vaccine, the 23-valent pneumococcal polysaccharide vaccine, and the human papillomavirus vaccine were provided free of charge in 1, 10 and 15 provinces, respectively. For these policies, the corresponding covered population and the proportion among the total applicable population were children aged 6 months to 2 years old (2.5%), older people (1.2% to 21.5%) and middle school girls (1.1% to 12.2%). Medical insurance payment policies were implemented in 14 provinces, and nearly covered the four types of vaccines in the policy implementation areas, with the proportion of the covered population about 10.9% to 41.5% among the total applicable population.
Subject(s)
Child , Female , Humans , Infant , Aged , Pneumococcal Vaccines , Vaccination , Policy , Immunization Programs , Papillomavirus Vaccines , China , Vaccines, ConjugateABSTRACT
Objective: To systematically collect and evaluate the health economics research of Human papilloma virus(HPV) vaccination population expansion to men, and to provide evidence for optimizing HPV vaccine immunization strategies. Methods: Health economics research studies on male HPV vaccination published in databases including PubMed, Web of Science, CNKI, and Wanfang Database from January 2010 to September 2022 were collected according to the systematic evaluation research design. The quality of the studies was assessed using the health economics evaluation reporting standards (2022 edition) (CHEERS 2022), with full score of 28. The results of the studies were reviewed and analyzed systematically. Results: A total of 21 studies complies with the criteria were included, all of which was foreign research. The average CHEERS score of the literatures was 25.71 points, range from 23 to 28 points. 85.71% (12/14) studies of the gender-neutral population showed that including male in HPV vaccination were more consistent with the cost effectiveness than female vaccination alone under certain conditions (target at adolescents of 10 to 15 years old or adults under 26 years old). 80.00% (4/5) of the studies target at ordinary men only were proved that male vaccination with HPV vaccine was in line with the cost-effectiveness. 2 studies targeting men who have sex with men (MSM) were both concluded that it met the cost-effectiveness. In addition, the results of 2 gender-neutral population studies and 1 study on men alone showed that extending HPV vaccination to men did not conform to cost effectiveness. The main reasons for the non-cost-effectiveness included the high price of vaccines and the age of vaccination. Conclusion: The quality of the health economics evaluation studies on expanding HPV vaccination to the male population is high. Vaccination targeting adolescents and young men as well as special groups (such as MSM) are likely to be cost-effective, and vaccinations for other groups are still need further evaluated. It is recommended that relevant research should be conducted to provide evidence for expanding the scope of HPV vaccination to men in China.
Subject(s)
Adult , Adolescent , Humans , Male , Female , Child , Papillomaviridae , Homosexuality, Male , Papillomavirus Infections/prevention & control , Sexual and Gender Minorities , Cost-Benefit Analysis , Vaccination , Immunization , Papillomavirus VaccinesABSTRACT
Objective: To understand the setting of adult vaccination clinics and the situation of adult vaccination in Shandong province, and provide the date basis for the construction and development of adult vaccination clinics in Shandong province. Methods: Multi-stage stratified cluster random sampling was used to survey the settings, personnel allocation, operation status, and adult vaccination status of child-adult vaccination clinics and adult vaccination clinics. A random sampling survey was conducted for hydrophobia vaccination clinics in 12 counties (cities, districts) of Shandong province. The settings and vaccination status of different types of adult vaccination clinics were compared and analyzed using analysis of variance or χ2-test. Results: Among the investigated counties (cities, districts), the child-adult vaccination clinics, the adult vaccination clinics, and the hydrophobia vaccination clinics accounted for 59.51%, 7.97% and 32.52%, respectively. The construction model could be divided into three models: child-adult vaccination clinic model, child-adult and hydrophobia vaccination clinic model, child-adult, adult and hydrophobia vaccination clinic model. The child-adult vaccination clinics had been set up for a long time (≥3 years accounted for 94.33%) and were set up by public primary medical institutions (public institutions accounted for 93.81% and primary institutions accounted for 92.78%). Each vaccination clinic was equipped with full-time and part-time staff of (3.19±3.01) and (3.72±4.32). The adult vaccination clinics had been set up for a short time (≥3 years accounted for 94.33%) and were set up by public/private primary/secondary medical institutions in urban areas (urban areas accounted for 100%, primary institutions accounted for 69.23%, and private institutions accounted for 57.69%). Each vaccination clinic was equipped with full-time and part-time staff of (2.46±2.87) and (3.08±3.53). The coverage of influenza vaccine (InfV), human papillomavirus vaccine (HPV) and hepatitis B vaccine (Hep B) reached 100%, 98.45% and 97.42% in children-adult vaccination clinics, and 88.46%, 84.62% and 73.08% in adult vaccination clinics, respectively. The hydrophobia vaccination clinics only provided rabies vaccine for human use (RabV) and tetanus vaccine (TV) vaccination simultaneously. A total of 819.8 thousand doses of adult vaccines were administered in 2021. The adult inoculation doses of RabV, lnfV and HPV accounted for 42.60%, 27.47% and 17.54% of the total inoculation doses, respectively. The inoculation doses of InfV, HPV and RabV accounted for 49.33%, 21.97% and 13.80% of child-adult vaccination clinics, respectively. The inoculation doses of HPV, HepB and RabV accounted for 49.36%, 15.40% and 14.71% of adult vaccination clinics, respectively. The proportion of RabV reached 94.44% in the hydrophobia vaccination clinics alone. Conclusion: Adult vaccination is at the initial stage in Shandong province. The children's vaccination clinic is mainly responsible for adult vaccination. The variety of adult vaccines is relatively concentrated, and the adult vaccination rate is lower. The construction and publicity of adult vaccination should be further strengthened.
Subject(s)
Adult , Humans , Papillomavirus Infections , Rabies , Influenza Vaccines , Vaccination , Ambulatory Care Facilities , Papillomavirus VaccinesABSTRACT
Objective: To understand the current situation of vaccination services for adults in China, explore how to establish a stable and efficient vaccination service system for adults, and provide reference for formulating corresponding policies. Methods: The vaccination information systems of nine provinces in China were used to obtain information on urban and rural vaccination of influenza vaccine, 23-valent pneumococcal polysaccharide vaccine (PPV23), and human papillomavirus vaccine (HPV) from 2019 to 2021. The indicator, vaccination rate/full vaccination rate, was used for statistical description. Results: The vaccination rate/full vaccination rate of the three vaccines in eastern China was generally higher than that in central and western China. The vaccination rate/full vaccination rate in urban areas was generally higher than that in rural areas. From 2019 to 2021, the vaccination rates of influenza vaccine among people aged 60 years and above in urban and rural areas were 2.96%, 6.29%, 6.14% and 1.29%, 2.58%, 2.94%, respectively. The vaccination rates of the PPV23 among people aged 60 years and above in urban and rural areas increased year by year, with rates of 0.38%, 1.05%, 1.15% and 0.14%, 0.49%, 0.59%, respectively. From 2019 to 2021, the HPV coverage of female adults aged 27-45 years in urban and rural areas increased year by year, with rates of 0.46%, 0.93%, 1.88% and 0.17%, 0.40%, 1.08%, respectively. Conclusion: The vaccination rates of influenza vaccine,PPV23 vaccine and HPV vaccine for adults in China are relatively low, with higher rates in the eastern region than in the central and western regions, and higher rates in urban areas than in rural areas. It is recommended to formulate corresponding health and economic policies and explore a suitable vaccination service system for adults in China to improve vaccination rates.